CDLX AI Price Prediction

The negative EPS of -2.00 and a corresponding negative PE ratio indicate that Cardlytics remains unprofitable, with losses substantial relative to its share price. Without evidence of improving margins or a clear path to profitability, current financial performance is a headwind for the stock.

• Negative EPS of -2.00 signals ongoing net losses and an absence of current earnings support for the share price.
• PE ratio of -0.35 reflects that investors are valuing the company despite losses, but at a very depressed multiple, consistent with distressed or turnaround expectations.
• Lack of positive profitability metrics (no positive PE, no indication of net income improvement) suggests that fundamental earnings momentum is weak and remains a key risk factor.

Cardlytics trades at $0.69, well below its 200-day moving average of $1.23, indicating a pronounced downtrend. The 25.5% decline over the last month underscores negative momentum and weak investor confidence.

• Current price of $0.69 is materially below the 200-day moving average of $1.23, a classic sign of a sustained bearish trend.
• A 25.5% drop in the last month reflects strong downside momentum and suggests ongoing selling pressure or capitulation risk.
• With the stock trading under $1, there is added risk of perceived distress and potential exchange-listing concerns if weakness persists, which can further weigh on sentiment.

Overall, Cardlytics’ setup appears bearish, with a deeply discounted share price, negative earnings, and a clear technical downtrend. Alternative data does not yet show strong positive inflections that would offset weak fundamentals and price momentum.

• Persistent losses (negative EPS and PE) combined with a sharp recent price decline and trading well below the 200-day moving average point to elevated fundamental and technical risk.
• Alternative data signals are mostly flat to slightly negative, suggesting cost discipline but not yet a compelling growth reacceleration that could catalyze a sustained recovery in the stock.